Furoscix Readyflow (autoinjector) is a drug owned by Scpharmaceuticals Inc A Wholly Owned Sub Of Mannkind Corp. It is protected by 10 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 30, 2040. Details of Furoscix Readyflow (autoinjector)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12491197 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | Active |
| US11497755 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide |
Jan, 2040
(13 years from now) | Active |
| US11571434 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide |
Jan, 2040
(13 years from now) | Active |
| US12491194 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | Active |
| US12491195 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | Active |
| US12491193 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | Active |
| US12048709 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | Active |
| US11998555 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | Active |
| US11559535 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide |
Jan, 2040
(13 years from now) | Active |
| US12491196 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Furoscix Readyflow (autoinjector) is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Furoscix Readyflow (autoinjector)'s family patents as well as insights into
ongoing legal events
on those patents.
Furoscix Readyflow (autoinjector)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Furoscix Readyflow (autoinjector)'s generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 30, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Furoscix Readyflow (autoinjector) Generic API suppliers:
Furosemide is the generic name for the brand Furoscix Readyflow (autoinjector). 32 different companies have already filed for the generic of Furoscix Readyflow (autoinjector), with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Furoscix Readyflow (autoinjector)'s generic
Alternative Brands for Furoscix Readyflow (autoinjector)
There are several other brand drugs using the same active ingredient (Furosemide) as Furoscix Readyflow (autoinjector). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Scpharmaceuticals |
| |
| Sq Innovation |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Furosemide, Furoscix Readyflow (autoinjector)'s active ingredient. Check the complete list of approved generic manufacturers for Furoscix Readyflow (autoinjector)
About Furoscix Readyflow (autoinjector)
Furoscix Readyflow (Autoinjector) is a drug owned by Scpharmaceuticals Inc A Wholly Owned Sub Of Mannkind Corp. Furoscix Readyflow (Autoinjector) uses Furosemide as an active ingredient. Furoscix Readyflow (Autoinjector) was launched by Scpharmaceuticals in 2022.
Approval Date:
Furoscix Readyflow (autoinjector) was approved by FDA for market use on 07 October, 2022.
Active Ingredient:
Furoscix Readyflow (autoinjector) uses Furosemide as the active ingredient. Check out other Drugs and Companies using Furosemide ingredient
Dosage:
Furoscix Readyflow (autoinjector) is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 80MG/ML (80MG/ML) | SOLUTION | Prescription | SUBCUTANEOUS |